45.53
3.01%
+1.33
SpringWorks Therapeutics Inc stock is currently priced at $45.53, with a 24-hour trading volume of 877.94K.
It has seen a +3.01% increased in the last 24 hours and a -7.46% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $43.72 pivot point. If it approaches the $45.68 resistance level, significant changes may occur.
Previous Close:
$44.20
Open:
$44.04
24h Volume:
877.94K
Market Cap:
$3.37B
Revenue:
-
Net Income/Loss:
$-325.10M
P/E Ratio:
-9.3491
EPS:
-4.87
Net Cash Flow:
$-230.18M
1W Performance:
+13.54%
1M Performance:
-7.46%
6M Performance:
+100.13%
1Y Performance:
+95.83%
SpringWorks Therapeutics Inc Stock (SWTX) Company Profile
Name
SpringWorks Therapeutics Inc
Sector
Industry
Phone
203 883 9490
Address
100 Washington Boulevard, Stamford, CT
SpringWorks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-05-24 | Initiated | Guggenheim | Buy |
Dec-01-22 | Initiated | BofA Securities | Buy |
Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
May-05-20 | Initiated | Barclays | Overweight |
Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
Dec-04-19 | Initiated | H.C. Wainwright | Buy |
Oct-08-19 | Initiated | Cowen | Outperform |
Oct-08-19 | Initiated | Goldman | Buy |
Oct-08-19 | Initiated | JP Morgan | Overweight |
Oct-08-19 | Initiated | Wedbush | Outperform |
View All
SpringWorks Therapeutics Inc Stock (SWTX) Latest News
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
GlobeNewswire Inc.
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
GlobeNewswire Inc.
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
GlobeNewswire Inc.
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
GlobeNewswire Inc.
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
SpringWorks Therapeutics Inc Stock (SWTX) Financials Data
SpringWorks Therapeutics Inc (SWTX) Net Income 2024
SWTX net income (TTM) was -$325.10 million for the quarter ending December 31, 2023, a -17.19% decrease year-over-year.
SpringWorks Therapeutics Inc (SWTX) Cash Flow 2024
SWTX recorded a free cash flow (TTM) of -$230.18 million for the quarter ending December 31, 2023, a -34.01% decrease year-over-year.
SpringWorks Therapeutics Inc (SWTX) Earnings per Share 2024
SWTX earnings per share (TTM) was -$5.15 for the quarter ending December 31, 2023, a +1.15% growth year-over-year.
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Cap:
|
Volume (24h):